Search - tctmd.com

Displaying 661 - 671 of 671

Presentation TCT 2012

Genetic Determinants of Clopidogrel Responsiveness in Koreans

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation TCT 2012

Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in Patients with Renal Insufficiency and Suspected Heparin-Induced Thrombocytopenia.

Presenter: James W. Wisler, Jeffrey B. Washam, Richard C. Becker

January 03, 2012

Presentation TCT 2012

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Presenter: Michael V. Holmes

January 03, 2012

Presentation TCT 2012

Comparison of bivalirudin versus heparin during PCI in patients receiving prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick, Y Wang, GP Steg, E...

Presenter: Martial Hamon

January 03, 2012

Presentation TCT 2012

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Presenter: Ping-Yen Liu, Ling-Jay Hsu, Po-Tseng Lee, Cheng-Hann Lee, Ju-Yi Chen, Yi-Heng Li, Liang-Miin Tsai, Jyh-Hong Chen

January 03, 2012

Presentation TCT 2012

Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary Percutaneous Coronary Intervention

Presenter: Dinna K. Soon, Hee Hwa Ho, Kwok Kong Loh, Yau Wei Ooi, David Foo, Paul Ong, Fahim Jafary

January 03, 2012

Presentation TCT 2012

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

Presenter: Erin M. Galbraith, Roxana Mehran, Chandan Devireddy, Henry A. Liberman, Steven V. Manoukian, Michele D. Voeltz

January 03, 2012

Presentation TCT 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Presenter: Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude

January 03, 2012

Presentation TCT 2012

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

Presenter: Paul S. Rees, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Presentation TCT 2012

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Presenter: Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek

January 03, 2012

Advertisement

Genetic Determinants of Clopidogrel Responsiveness in Koreans

Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in Patients with Renal Insufficiency and Suspected Heparin-Induced Thrombocytopenia.

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Comparison of bivalirudin versus heparin during PCI in patients receiving prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick, Y Wang, GP Steg, E...

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary Percutaneous Coronary Intervention

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content